Zyprexa Shortage: What Providers and Prescribers Need to Know in 2026

While oral olanzapine remains broadly available in 2026, the injectable formulations have experienced documented supply disruptions. This clinical brief covers what prescribers need to know about the current olanzapine supply landscape, injectable shortage management, appropriate therapeutic alternatives, and how to help patients access their medication consistently.

Current Supply Status by Formulation (2026)

Providers should be aware of the distinct availability profiles for different olanzapine formulations:

Oral tablets (2.5–20 mg): Not in national shortage. Multiple generic manufacturers maintain supply. Minor regional or dose-specific gaps possible.

Orally disintegrating tablets (5–20 mg): Generally available; may require advance ordering at smaller pharmacies. Bioequivalent to tablets when oral administration adherence is a concern.

Short-acting IM (10 mg vial): Has had documented shortage listings on ASHP's tracker. Hospital and ED pharmacies should maintain updated supplier information. Consider alternatives (haloperidol IM, lorazepam) per institutional protocols if unavailable.

Zyprexa Relprevv (LAI, 150–300 mg): Requires REMS enrollment for administering facilities. International supply constraints were documented in 2024 (UK NHS resolution February 2024). Monitor US REMS-registered facility supply separately.

Managing the IM Olanzapine Shortage in Acute Settings

Short-acting intramuscular olanzapine (Zyprexa IntraMuscular, 10 mg) is commonly used for acute agitation in patients with schizophrenia or bipolar I disorder. If your hospital pharmacy has limited or no stock, consider the following alternatives, consistent with your institution's protocols:

Haloperidol IM: First-generation antipsychotic; well-studied for acute agitation. Higher EPS risk. Often combined with lorazepam for enhanced effect.

Droperidol IM: May be available at some institutions; monitor for QTc prolongation.

Ziprasidone IM: Available at some facilities; note QTc concerns and requirement for cardiac monitoring in some populations.

Important: Do not combine IM olanzapine with IM or IV benzodiazepines due to risk of significant respiratory depression. This contraindication applies when the combination is being considered regardless of shortage status.

Managing Zyprexa Relprevv Gaps for Outpatient Patients

If Zyprexa Relprevv is unavailable at a patient's REMS-registered injection site, consider:

Bridging with oral olanzapine while the injection is sourced. Use weight-based dosing equivalents and the patient's historical effective oral dose as guidance.

Transitioning to an alternative LAI antipsychotic (e.g., aripiprazole monohydrate [Abilify Maintena] or paliperidone palmitate [Invega Sustenna]) if the patient's clinical profile is compatible. This decision requires careful cross-taper planning.

Document clinical rationale and patient consent for any formulary-driven changes to LAI therapy. Patients with LAI treatment histories may have specific reasons for injectable vs. oral therapy that must be factored in.

Oral Olanzapine: Appropriate Therapeutic Alternatives

If a patient cannot access oral olanzapine due to a localized stock gap, the following atypical antipsychotics share FDA approvals for schizophrenia and/or bipolar I disorder and are widely available as generics:

Risperidone: D2/5-HT2A antagonist; lower metabolic burden; higher prolactin elevation; available as ODT (Risperdal M-Tab) and LAI (Risperdal Consta).

Quetiapine: D2/5-HT2A antagonist; sedating; similar metabolic risk to olanzapine; no LAI formulation.

Aripiprazole: Partial D2 agonist; lower metabolic risk; higher akathisia incidence; monthly LAI available (Abilify Maintena).

Cross-taper protocols should be individualized. Abrupt discontinuation of olanzapine and immediate initiation of an alternative risks destabilization, withdrawal symptoms (including cholinergic rebound with nausea/diaphoresis), and rebound psychosis.

Helping Patients Find Olanzapine in Stock

For patients who report difficulty finding oral olanzapine at their pharmacy, recommend these steps:

Call multiple pharmacies — stock varies by pharmacy and manufacturer.

Ask your prescriber to send the prescription to a different pharmacy that has stock.

Consider switching to 90-day mail-order pharmacy fills for improved supply stability.

medfinder for providers can assist patients in locating pharmacies with their medication in stock — a useful recommendation to include in your patient education workflow.

Documentation and Formulary Considerations

If a patient is switched to an alternative antipsychotic due to availability issues, document the following in the medical record: the shortage or access barrier as the reason for the change, the patient's response to the switch, and any plans to return to olanzapine when supply normalizes. This documentation supports prior authorization appeals and continuity of care across providers.

For more on helping patients save on olanzapine, see our guide to Zyprexa savings programs for providers.